Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311039 | 1.00 | LMNA (0.46) | LMNATP53CNR2ADORA1ADORA3 | |
| SCHEMBL11961123 | 0.92 | LMNA (0.48) | LMNATP53ADORA1ADORA3ADORA2A | |
| SCHEMBL30332447 | 0.84 | LMNA (0.50) | LMNATP53ADORA1ADORA3ADORA2A | |
| SCHEMBL786767 | 0.84 | LMNA (0.50) | LMNATP53ADORA1ADORA3ADORA2A | |
| SCHEMBL14983397 | 0.82 | ADORA2A (0.47) | TP53CNR2ADORA1ADORA3ADORA2A | |
| SCHEMBL786455 | 0.81 | ADORA2A (0.49) | LMNATP53ADORA1ADORA3ADORA2A | |
| SCHEMBL16714635 | 0.81 | ADORA2A (0.49) | LMNATP53ADORA1ADORA3ADORA2A | |
| SCHEMBL30332114 | 0.81 | ADORA2A (0.49) | LMNATP53ADORA1ADORA3ADORA2A | |
| SCHEMBL12537370 | 0.80 | PIK3CA (0.44) | CNR2ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL786016 | 0.80 | ADORA2A (0.50) | LMNATP53ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524604-B1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3524604-A1 | EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2019-08-14 | — | — | EP | disclosed |
| EP-2350078-B1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2019-04-17 | — | — | EP | disclosed |
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9580426-B2 | Compounds that expand hematopoietic stem cells | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| US-8927281-B2 | Method for expanding hematopoietic stem cells | IRM LLC (BM) | 2015-01-06 | — | — | US | disclosed |
| WO-2014138485-A1 | EX VIVO PRODUCTION OF PLATELETS FROM HEMATOPOIETIC STEM CELLS AND THE PRODUCT THEREOF | IRM LLC (BM) | 2014-09-12 | — | — | WO | disclosed |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2350078-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2011-08-03 | — | — | EP | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239296-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | LMNA 4540/4885TP53 830/4885CNR2 4185/4885 |
| US-20210187033-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | LMNA 4540/4885TP53 830/4885CNR2 4185/4885 |
| US-20140114070-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | LMNA 4540/4885TP53 830/4885CNR2 4185/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | LMNA 4540/4885TP53 830/4885CNR2 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.